JPMorgan Downgrades ResMed (RMD:AU) (RMD) to Neutral
- Futures inch lower ahead of unemployment, retail sales data
- Electronic Arts (EA) Rebounds on Reaffirmed Guidance Despite Battlefield 2042 Delay, Be Concerned But Not Worried Says Analyst
- Coinbase (COIN) Applies to Trade Bitcoin, Crypto Futures
- Dollar edges higher with focus on Fed for taper clues
- Cisco Systems (CSCO) Upgraded to Outperform at Credit Suisse, Other Analysts Raise PTs Following Bullish Investor Day
JPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Overweight to Neutral with a price target of AUD33.50.
You May Also Be Interested In
- Auto Suppliers: BofA Downgrades Lear (LEA) and Visteon (VC) to Underperform on Valuation, Upgrades Dana (DAN) to Buy
- Hengan International Group (1044:HK) (HEGIY) PT Lowered to HK$46 at Morgan Stanley
- DoorDash (DASH) Soars as BofA Upgrades to Buy on Upside to 2021 Estimates and Robust Mid-term Growth Opportunity
Create E-mail Alert Related CategoriesDowngrades, Intl Ratings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!